February 27, 2025 | Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, evaluate the clinical data supporting amivantamab plus lazertinib in EGFR-mutated NSCLC. Neal outlines the mechanistic rationale for dual EGFR and MET targeting and reviews efficacy outcomes from pivotal studies. Goldberg contextualizes this combination within current sequencing strategies and frontline decision-making.
Related Posts
Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC
Navigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk Features
AE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLC
How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLC
